Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Umbilical Cord Blood Injection for Critical Limb Ischemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Atherosclerotic ischemic peripheral vascular disease or Thromboangiitis Obliterans with Critical Limb Ischemia (Fontaine stages III and IV)~* Participant must match either a or b~  1. Ankle brachial index (ABI) ≤ 0.7~ 2. Doppler waveforms at posterior tibial artery and dorsalis pedis artery are monophasic with toe pressure \< 30 mmHg.~* A non-surgical candidate for revascularization e.g. prior vascular reconstruction, inability to locate a suitable vein for grafting, diffuse multi- segment disease, or extensive infra-popliteal disease not amenable to a vascular graft.~* Age \> 18 years old.~* The non-index leg may be treated only in the event and it full fills the same eligibility criteria and exclusion criteria used in this protocol for the treatment leg.~* Patients must be on maximal tolerated medical therapy for PVD including A) Cessation of smoking B) Referral to endocrinologist for control of HgA1c to \< 7.0 mg/dl, control of hyperlipidemia with statins or other anti-hyperlipidemic drugs as indicated, control of hypertension as indicated C) Antiplatelet therapy with aspirin and / or cilostazol (unless medically contraindicated, e.g. bleeding or allergy)~Exclusion Criteria:~* Popliteal vascular entrapment syndrome~* Lower extremity infection or infected ulcer~* Hypercoagulable state~* HIV positive~* HBsAg positive~* Uncontrolled arrhythmia, that is, persistence of an arrhythmia despite medical therapy~* Unstable angina~* Thrombocytopenia \< 50,000/ul~* Leukemia or myelodysplasia~* Allergy to E coli or its products~* Patients with metal in their bodies cannot undergo MRIs (MRA). Therefore, patients with, cochlear implants, or aneurysm clips are not eligible. Coronary artery stents are not a contraindication. Patients with pacemakers are still candidates provided they have normal creatinine (\< 1.1 mg/dl) and can receive contrast dye (no allergy) for angiogram instead of MRA. MRI/MRA does not need to be repeated if a prior MRA or Angiogram Demonstrates inoperable disease.~* Patients who are pregnant~* Poorly controlled diabetes will not be a cause for exclusion but patient must see endocrinologist for better control~* Current malignancy, except squamous cell or basal cell skin cancers thought to be easily controlled.~* AST, ALT, or bilirubin more than twice the upper limit of normal.~* WBC \< 2.5 / ul.~* Any patient who is actively bleeding, including blood on urine dipstick or fecal occult blood.~* Patient is on chemotherapy or other immuno-suppressive medications such as steroids, cellcept, cyclosporine, cytoxan, azathioprine, rituxan, humira or remicade.~* Donor is HLA homozygous and shares that HLA haplotype with the recipient (a different donor will have to be found)~* Patients diagnosed with Thromboangiitis Obliterans (Buerger's Disease) who are smokers and are unwilling or unable to quit smoking~* A) Patients with a myocardial infarction within the last 30 days or left ventricular ejection fraction \< 35% B) Patients with a history of malignancy in the last 5 years (other than basal cell carcinoma or carcinoma in situ) C) Patients with a CVA within the last 6 months D) Patients with a HbA1c level \> 7.0%

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 72 Years
- Healthy Volunteers: f

Study Arms:
- UBC injection into one leg of PVD pt (Type: EXPERIMENTAL): 25 participants with severe peripheral vascular disease in leg(s) and they do not qualify for surgical treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).